Replimune is resubmitting its twice-rejected melanoma drug after FDA leadership exodus
2 distinct publishers, one article each in this sample.
Ownership mix: Other: 2
2 publishers · 2 articles · switch to 1-minute for disagreement and framing.
What happened
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.
Why the coverage differs
AI-assisted comparison · labeled · generated Aug 28, 2026, 6:11 AM · not a verdict
What happened: Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Where coverage diverges: Center: 2 (CNBC — Top, Quartz).
Comparison summary
AI-assisted · Cerebras / Llama · Aug 28, 2026, 6:11 AM · inspect sources below rather than trusting this alone
What happened: Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Where coverage diverges: Center: 2 (CNBC — Top, Quartz).
What's missing: AI bias-comparison is temporarily offline. Configure Cerebras in admin to enable rich comparison summaries.
Report timeline
Oldest → newest among clustered members. Gaps may mean delayed pickup, not silence.
-
May 29, 2026, 5:51 AMCNBC — Top · CenterReplimune to resubmit twice-rejected drug for approval after FDA shakeup
-
May 29, 2026, 7:10 AM
Coverage by perspective
Perspective labels are external consensus ratings (AllSides / Ad Fontes / MBFC-style), not WeSearch truth scores. Center is not automatically more accurate.
Center · 2
Headline framing
Vocabulary fingerprints · not a political endorsement
AI framing analysis temporarily offline. Configure Cerebras in admin to enable framing comparison.
Bias/ownership: published methodology on source profiles · AI text always labeled · no reader paywall · no engagement ranking of news · transparency · contribute Ws · home